Welcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires blanketed much of the US Northeast this week. Hopefully ...
July 18, 2026 06:00 AM EDT
Weekly
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more
Max Gelman
Nicole DeFeudis
Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan…
Welcome back to Endpoints Weekly. The biggest news this week was Marty Makary’s resignation from his role as FDA Commissioner.…
Welcome back to Endpoints Weekly! We’re gearing up for a busy week of earnings coverage, as Moderna, AstraZeneca, GSK, Bristol…
Welcome to another edition of Endpoints Weekly, and happy August! The summer is speeding right along, and we’ve got the latest…
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
The end for GSK's chronic cough treatment
